Introduction
cancers, death, tumor, malignancy, cancer
CANCERS, TUMOR, CANCER, ADENOCARCINOMA, ONCOLOGY
Gastric and gastroesophageal junction (G/GEJ) cancers represent the fifth most common newly diagnosed malignancy and the fourth leading cause of cancer-related death worldwideAccording to the guidelines of the Chinese Society of Clinical Oncology (CSCO), a combination of perioperative therapy and D2 gastrectomy is currently considered the standard treatment option for locally advanced G/GEJ cancers (cTImmune checkpoint inhibitors that target programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have shown promising survival benefits and manageable safety in first-line treatment of patients with G/GEJ cancers in the CheckMate-649In recent studies, it has been demonstrated that conventional cancer therapies, including chemotherapy and radiotherapy, alter the tumor immune microenvironment (TiME) (e.g., increasing the expression levels of immune checkpointsSintilimab, a fully human and highly selective anti-programmed death (PD)-1 monoclonal antibody, binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, causing a robust antitumor effectHence, in this multicenter, single-arm phase 2 trial, we aim to evaluate the efficacy and safety of perioperative sintilimab plus cCRT in patients with locally advanced G/GEJ cancers. Further, we conduct an exploratory multiplex immunofluorescence (mIF) analysis of TiME with the aim of identifying promising biomarkers of treatment response. Here, we show the promising efficacy and manageable safety profile of sintilimab in combination with concurrent chemoradiotherapy for the perioperative treatment of locally advanced G/GEJ adenocarcinoma.